Avtor/Urednik		Korde, Larissa A; Lusa, Lara; McShane, Lisa; Lebowitz, Peter F; Lukes, LuAnne; Camphausen, Kevin; Parker, Joel S; Swain, Sandra M; Hunter, Kent; Zujewski, Jo Anne
Naslov		Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer
Tip		članek
Vir		Breast Cancer Res Treat
Leto izdaje		2009
Jezik		eng
Abstrakt		Neoadjuvant chemotherapy has been shown to be equivalent to post-operative treatment for breast cancer, and allows for assessment of chemotherapy response. In a pilot trial of docetaxel (T) and capecitabine (X) neoadjuvant chemotherapy for Stage II/III BC, we assessed correlation between baseline gene expression and tumor response to treatment, and examined changes in gene expression associated with treatment. Patients received four cycles of TX. Tumor tissue obtained from Mammotome core biopsies pretreatment (BL) and post-cycle 1 (C1) of TX was flash frozen and stored at -70 degrees C until processing. Gene expression analysis utilized Affymetrix HG-U133 Plus 2.0 GeneChip arrays. Statistical analysis was performed using BRB Array Tools after RMA normalization. Gene ontology (GO) pathway analysis used random variance t tests with a significance level of P < 0.005. For gene categories identified by GO pathway analysis as significant, expression levels of individual genes within those pathways were compared between classes using univariate t tests; those genes with significance level of P < 0.05 were reported. PAM50 analyses were performed on tumor samples to investigate biologic subtype and risk of relapse (ROR). Using GO pathway analysis, 39 gene categories discriminated between responders and non-responders, most notably genes involved in microtubule assembly and regulation. When comparing pre- and post-chemotherapy specimens, we identified 71 differentially expressed gene categories, including DNA repair and cell proliferation regulation. There were 45 GO pathways in which the change in expression after one cycle of chemotherapy was significantly different among responders and non-responders. The majority of tumor samples fell into the basal-like and luminal B categories. ROR scores decreased in response to chemotherapy; this change was more evident in samples from patients classified as responders by clinical criteria. (Abs. trunc. at 2000 ch.)
Deskriptorji		BREAST NEOPLASMS CHEMOTHERAPY, ADJUVANT GENE EXPRESSION BIOPSY DNA REPAIR TREATMENT OUTCOME